STAT

We wish we’d written that: STAT staffers share their favorite stories of 2018

It's time for STAT's annual admission of jealousy: We share our favorite stories of 2018 — that we wish we would have written.

It’s been a busy 2018 here at STAT, reporting on the latest on “CRISPR babies,” drug pricing squabbles, IBM Watson, and the ongoing Ebola outbreak, just to name a few. But we, of course, still find the time to see what other journalists are writing — and get jealous we didn’t do it ourselves.

So as we take a little breather before 2019 ramps up, we present another year of the stories we wish we would have written.

Speaking of jealousy, we must admit we got the idea for this list from Bloomberg Businessweek — so head over there for more great reporting from the year that was.

Story of a Face: How a Transplanted Face Transformed Katie Stubblefield’s Life

By Joanna Connors, Photos by Lynn Johnson and Maggie Steber, National Geographic

At age 21, Katie Stubblefield was the youngest person in the United States to receive a face transplant. Photographers Lynn Johnson and Maggie Steber documented this process before, during, and after surgery. Steber photographed tender, quiet moments of Stubblefield and her family in the months leading up to surgery while Johnson captured the surreality of the operating room. This long-term project is a remarkable story spanning science, medicine, and personal

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks